In Case You Missed It: Lithium does the heavy lifting today
Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today.
It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms.
Stocks highlighted in green have made market-moving announcements (click headings to sort).
Kula Gold (ASX:KGD) reckons there’s evidence of “bladed spodumene crystals at surface” over a large area at the recently acquired Kirup project, ~20km from the world’s largest hard rock lithium mine Greenbushes in WA.
Early-stage mapping/soil sampling has uncovered some drill targets to test for lithium below the weathered zone, which is estimated at 15-20m deep.
Assays are pending from a small four-hole for 360m drill program at the 1.7km-long DBGM gold-lithium prospect, also a proverbial stone’s throw (~45km) from Greenbushes.
WIA Gold (ASX:WIA) is getting thick and high-grade extensional drill hits, just weeks after unveiling a monster 1.3Moz maiden resource for the Kokoseb gold deposit in Namibia.
The company is already working toward its next resource upgrade with new intercepts like 15m at 17.13g/t from 292m.
Multiple lithium and REE targets have been identified at Fin Resources’ (ASX:FIN) early-stage Ross project in James Bay, Quebec.
Ross, which neighbours the Whabouchi lithium deposit (36.6Mt at 1.3% Li20), will be explored with detailed field mapping, outcrop sampling and geochemical sampling during Q3.
African lithium developer Leo Lithium (ASX:LLL) has bagged a cool cash injection from its JV partner on the Goulamina lithium mine in Mali, with China’s Ganfeng tipping $106.1 million into its 50-50 partner for a 9.9% stake.
The companies will look to increase the scale of the mine’s second phase to 500,000tpa, raising the prospects of turning Africa’s first spodumene operation into a million-tonnes-per-annum producer before the end of the decade.
Radiopharm Theranostics (ASX:RAD) completed a positive pre-Investigational New Drug (IND) meeting with the US FDA for F18-pivalate (RAD 101), which allows it to move towards its IND application for the company’s late-stage clinical trial.
Based on positive guidance received from the FDA, the company will file an IND application to initiate a multi-centre trial for imaging brain metastasis during the Q3 of 2023, and anticipates having the first patient dosed by the end of the year.
Advanced graphite play Black Rock Mining (ASX:BKT) has inked binding offtake and a US$10m prepayment facility with shareholder and US$20bn steel conglomerate POSCO to buy 100% of planned graphite fines production – between 20-30,000tpa – from Module 1 of the Mahenge project in Tanzania.
The US$10m prepayment, to be repaid with product, will be used as part of construction financing, BKT says, which is due for completion in the current quarter.
And Conico (ASX:CNJ) has flagged its latest assays at Mt Thirsty cobalt-nickel-manganese-scandium project are outside of the recent mineral resource estimate, and that there’s an opportunity for further resource growth and potentially mine life extensions.
At Stockhead we tell it like it is. While Kula Gold and Conico are Stockhead advertisers, they did not sponsor this article.